{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-005084","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.318504+00:00","generated_at":"2026-06-18T22:25:56.141702+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcus Biosciences Q4 net loss $67M; ARC-7 domvanalimab combo doubles PFS to 12 months","bullets":["Q4 2022 net loss $67M vs net income $280M in Q4 2021; full-year net loss $267M vs net income $53M.","Revenue $34M in Q4 2022, down from $355M in Q4 2021; cash $1.1B, sufficient into 2026.","ARC-7 interim data: domvanalimab+zimberelimab mPFS 12.0 months vs 5.4 months for zimberelimab alone.","Four ongoing registrational Phase 3 studies for domvanalimab; updated ARC-7 data expected at ASCO June 2023.","AB521 (HIF-2a inhibitor) Phase 1/1b enrolling 50mg cohort; initial data expected late 2023 or early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-005084","json":"https://secwatch.observer/filing/0000950170-23-005084.json","markdown":"https://secwatch.observer/filing/0000950170-23-005084.md","text":"https://secwatch.observer/filing/0000950170-23-005084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023005084/0000950170-23-005084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023005084/rcus-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:25:56.141702+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54209a89d32470be6bde0652b0cbd469bd83a96b","claim":"Arcus Biosciences, Inc. reported financial results for the three months and full year ended December 31, 2022.","evidence_excerpt":"On February 28, 2023, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three months and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023005084/0000950170-23-005084-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}